Serotonin News and Research

Latest Serotonin News and Research

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Many have recently questioned the efficacy of the most common antidepressant medications, the selective serotonin reuptake inhibitors (SSRIs). The conclusion that these drugs are ineffective is however partly based on a misinterpretation of the outcome of the clinical trials once conducted to demonstrate their efficacy. This was the finding of a study conducted by researchers at the Sahlgrenska Academy.

29 May 2015

Serotonin and TGF-beta pathways link diet to health and ageing

Diet exerts a major impact on health and ageing. The nervous system plays an important role in this process but, thus far, how food signals are interpreted by the nervous system has been a mystery.

14 May 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Specific brain chemical may play role in promoting chronic pain

A chemical in the brain typically associated with cognition, movement and reward-motivation behavior -- among others -- may also play a role in promoting chronic pain, according to new research at The University of Texas at Dallas.

7 May 2015

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.

6 May 2015

Researchers describe natural mechanism that helps repair lesions in teeth

Researchers at Inserm and Paris Descartes University have just taken an important step in research on stem cells and dental repair. They have managed to isolate dental stem cell lines and to describe the natural mechanism by which they repair lesions in the teeth. This fundamental discovery will make it possible to initiate unprecedented therapeutic strategies to mobilise the resident dental stem cells and magnify their natural capacity for repair.

23 Apr 2015

Prenatal antidepressant exposure increases anxiety symptoms

Three-year-old siblings exposed to antidepressants in pregnancy show increased anxiety symptoms compared to their unexposed siblings.

21 Apr 2015

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Bionomics Limited, a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the initiation of a Phase II clinical study of BNC210, the Company's drug candidate in development for the treatment of anxiety and depression.

20 Apr 2015

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ.

13 Apr 2015

Blueberries may be effective in treatment for PTSD

Up to 8 percent of people in the U.S. suffer from post-traumatic stress disorder (PTSD) as the result of witnessing or being the victim of a traumatic event. People with PTSD have been in a situation in which they were at risk of death, serious injury or sexual violence or have seen first-hand loved ones faces such threats. They may experience flashbacks, emotional detachment and jumpiness, among other symptoms that affect their ability to function in everyday life.

30 Mar 2015

Early response plus genetic variants strengthen antidepressant outcome prediction

Considering genetic variants in combination with early partial improvement could be useful for predicting antidepressant outcome, say researchers.

24 Mar 2015

Study investigates effects of antidepressant treatment in pain catastrophizing patients

A select population of patients having surgery experience what is called pain catastrophizing - an irrational thought process that leads a patient to perceive pain as worse than it actually is. Antidepressant medications reduce negative mood and might change this way of thinking, but according to a study published in the April edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, that may not be the case, at least for acute pain.

18 Mar 2015

Use of psychedelic drugs linked to less psychological distress, fewer suicidal thoughts

A history of psychedelic drug use is associated with less psychological distress and fewer suicidal thoughts, planning and attempts, according to new research from Johns Hopkins and the University of Alabama at Birmingham.

10 Mar 2015

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal.

5 Mar 2015

Lexicon updates drug development progress, reports 2014 financial results

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2014.

4 Mar 2015

Common antidepressant medications not helpful for people with mood, anxiety disorders

Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood.

4 Mar 2015

Anticholinergic medications associated with pneumonia risk in older people

Taking commonly used medications with anticholinergic effects is associated with a significantly higher risk for developing pneumonia in a study of more than 3,000 older Group Health patients living in the community--not in nursing homes.

3 Mar 2015

Vitamin D, omega-3 fatty acids may optimize brain serotonin concentrations and function

Although essential marine omega-3 fatty acids and vitamin D have been shown to improve cognitive function and behavior in the context of certain brain disorders, the underlying mechanism has been unclear. In a new paper published in FASEB Journal by Rhonda Patrick, PhD and Bruce Ames, PhD of Children's Hospital Oakland Research Institute, serotonin is explained as the possible missing link tying together why vitamin D and marine omega-3 fatty acids might ameliorate the symptoms associated with a broad array of brain disorders.

27 Feb 2015

Study explores association between back pain and depression

Genetic factors help to explain the commonly found association between low back pain and depression, suggests a large study of twins in the March issue of PAIN, the official publication of the International Association for the Study of Pain. The journal is published by Wolters Kluwer.

26 Feb 2015

Serotonin News and Research

Latest Serotonin News and Research

Helsinn's Akynzeo for CINV prevention receives EC approval

Study explores efficacy of selective serotonin reuptake inhibitors in reducing depressed mood

Serotonin and TGF-beta pathways link diet to health and ageing

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Specific brain chemical may play role in promoting chronic pain

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Researchers describe natural mechanism that helps repair lesions in teeth

Prenatal antidepressant exposure increases anxiety symptoms

Bionomics begins BNC210 Phase II clinical trial for treatment of anxiety, depression

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Blueberries may be effective in treatment for PTSD

Early response plus genetic variants strengthen antidepressant outcome prediction

Study investigates effects of antidepressant treatment in pain catastrophizing patients

Use of psychedelic drugs linked to less psychological distress, fewer suicidal thoughts

GeneSight test better predicts antidepressant outcomes for patients with depression

Lexicon updates drug development progress, reports 2014 financial results

Common antidepressant medications not helpful for people with mood, anxiety disorders

Anticholinergic medications associated with pneumonia risk in older people

Vitamin D, omega-3 fatty acids may optimize brain serotonin concentrations and function

Study explores association between back pain and depression

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Serotonin News and Research

Latest Serotonin News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in